Expression of concern:Adenovirus-mediated expression of truncated E2F-1 suppresses tumor growth in vitro and in vivo(Cancer., (2010), 116, (18), (4420-4432), 10.1002/cncr.25322);Adenovirus-mediated expression of truncated E2F-1 suppresses tumor growth in vitro and in vivo

Cancer

Volumn 116, Issue 18, 2010, Pages 4420-4432

  Gomez Gutierrez, Jorge G ^a   Garcia Garcia, Aracely ^a,b   Hao, Hongying ^a   Rao, Xiao Mei ^a   De Oca Luna, Roberto Montes ^b   Zhou, Heshan S ^a,b   McMasters, Kelly M ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Adenovirus; Apoptosis; Cancer; E2F 1; In vivo; Tetracycline off; Truncated

Indexed keywords

ADENOVIRUS VECTOR; TRANSCRIPTION FACTOR E2F1; E2F1 PROTEIN, HUMAN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE; CYTOTOXICITY; GENE TRANSFER; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG SCREENING; GENE DELETION; GENE THERAPY; GENE VECTOR; GENETICS; NEOPLASMS; PROCEDURES; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; E2F1 TRANSCRIPTION FACTOR; GENES, P53; GENETIC THERAPY; GENETIC VECTORS; MICE; MICE, INBRED BALB C; NEOPLASMS; SEQUENCE DELETION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77957361070     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.35435     Document Type: Erratum

References (31)

1. Dong YB, Yang HL, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer. 1999;86:2021-2033.
2. Dong YB, Yang HL, Elliott MJ, McMasters KM. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res. 2002;62:1776-1783.
3. Elliott MJ, Dong YB, Yang H, McMasters KM. E2F-1 upregulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin Cancer Res. 2001;7:3590-3597.
4. Vorburger SA, Hetrakul N, Xia W, et al. Gene therapy with E2F-1 up-regulates the protein kinase PKR and inhibits growth of leiomyosarcoma in vivo. Mol Cancer Ther. 2005;4:1710-1716.
5. Itoshima T, Fujiwara T, Waku T, et al. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res. 2000;6:2851-2859.
6. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365:349-352.
7. Muller H, Helin K. The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta. 2000;1470:M1-M12.
8. Fan J, Bertino JR. Functional roles of E2F in cell cycle regulation. Oncogene. 1997;14:1191-1200.
9. Bell LA, O'Prey J, Ryan KM. DNA-binding independent cell death from a minimal proapoptotic region of E2F-1. Oncogene. 2006;25:5656-5663.
10. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89:5547-5551.
11. Gomez-Gutierrez JG, Rao X-M, Garcia-Garcia A, Hao H, McMasters KM, Zhou HS. Developing adenoviral vectors encoding therapeutic genes toxic to host cells: comparing binary and single-inducible vectors expressing truncated E2F-1. Virology. 2010;397:337-345.
12. Gomez-Gutierrez JG, Souza V, Hao HY, et al. Adenovirus-mediated gene transfer of FKHRL1 triple mutant efficiently induces apoptosis in melanoma cells. Cancer Biol Ther. 2006;5:875-883.
13. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 1994;269:30761-30764.
14. Kuhn H, Liebers U, Gessner C, et al. Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis. Eur Respir J. 2002;20:703-709.
15. Bauer TW, Gutierrez M, Dudrick DJ, et al. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan. Surgery. 2003;133:420-428.
16. Canter RJ, Zhou R, Kesmodel SB, et al. Metaiodobenzyl-guanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma. Ann Surg Oncol. 2004;11:265-273.
17. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancers. Science. 1991;253:49-53.
18. Molenaar JJ, Ebus ME, Geerts D, et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A. 2009;106:12968-12973.
19. Sakaguchi M, Kataoka K, Abarzua F, et al. Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J Biol Chem. 2009;284:14236-14244.
20. Tang W, Wang W, Zhang Y, Liu S, Liu Y, Zheng D. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J. 2009;276:581-593.
21. Melillo RM, Helin K, Lowy DR, Schiller JT. Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins. Mol Cell Biol. 1994;14:8241-8249.
22. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 1997;11:1840-1852.
23. Agniswamy J, Fang B, Weber IT. Conformational similarity in the activation of caspase-3 and -7 revealed by the unliganded and inhibited structures of caspase-7. Apoptosis. 2009;14:1135-1144.
24. Yang HL, Dong YB, Elliott MJ, Liu TJ, McMasters KM. Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin Cancer Res. 2000;6:1579-1589.
25. Nguyen KH, Hachem P, Khor LY, et al. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. Int J Radiat Oncol Biol Phys. 2005;63:238-246.
26. Bessis N, Garcia-Cozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11(suppl 1):S10-S17.
27. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet. 2000;1:91-99.
28. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther. 2006;6:215-226.
29. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2008;132:1-14.
30. de Wilt JH, Bout A, Eggermont AM, et al. Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther. 2001;12:489-502.
31. Hannay J, Davis JJ, Yu D, et al. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther. 2007;14:671-681.